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published NMAs have accounted for this variable when assessing the relative 
efficacy of CHB interventions. We undertook baseline-adjusted and -unadjusted 
analyses using the same dataset to explore the impact of BVL on UVL 
achievement. METHODS: The NMA was undertaken in WinBUGs using standard 
fixed/random effects approaches. A systematic literature review was the source 
of efficacy data for eight interventions. Individual patient data from an entecavir 
RCT was used to quantify the impact of different baseline characteristics on the 
likelihood of achieving UVL at one year. Study level mean baseline values from 
all identified papers and the results from the abovementioned analysis were 
used to inform prior distributions in the adjusted analysis. Results were 
presented as relative risks (RRs) at one year and 95% credible intervals. Entecavir 
was the reference treatment. Sensitivity analyses surrounding the 
inclusion/exclusion of individual studies were performed. RESULTS: Entecavir 
and tenofovir studies included heterogeneous patient populations in terms of 
BVL (mean entecavir value 9.29 log10copies/ml, tenofovir value 8.65 
log10copies/ml). After adjusting the UVL for baseline viral load using an 
informative prior, the RR for entecavir versus tenofovir went from statistically 
significant to non-significant [unadjusted: RR 1.43 (1.30 to 1.54), adjusted: RR 1.21 
(0.48 to 1.51)]. Relative efficacy results for all other interventions were similar 
across adjusted and unadjusted analyses. Adjusted results were robust to the 
inclusion/exclusion of additional studies. Adjusted results for all interventions 
were consistent with clinical trial data. CONCLUSIONS: Adjusted and unadjusted 
NMA, using the same dataset, demonstrated the importance of adjusting for BVL 
when assessing the relative efficacy of CHB interventions. Failing to account for 
differences in BVL across studies may result in flawed relative efficacy estimates.  
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OBJECTIVES: In absence of head-to-head trials and over hundred new molecules 
in clinical development for hepatitis C virus (HCV) infection, mixed treatment 
comparisons continue to play a crucial role in guiding clinical decision making. 
This study was aimed to identify the practical challenges of conducting mixed 
treatment comparisons in chronic HCV genotype-1 patients, especially in 
subgroups with clinical factors that are associated with poor treatment response 
and/or increased risks. METHODS: A systematic review was conducted to 
identify randomized controlled trials of telaprevir (TVR) and boceprevir (BOC) in 
HCV genotype-1 patient population. Included clinical trials were assessed to 
check: 1) if clinical factors related to poor treatment response (race, prior viral 
load, grade of underlying cirrhosis/fibrosis) were reported and subgroup analyses 
were conducted; and 2) if important safety endpoints (rash, anemia, 
neutropenia) were reported with a clear definition of the gradient of severity. 
RESULTS: A total of eight trials were identified: five in treatment-naïve patients 
(4TVR, 1BOC) and three in treatment-experienced patients (2TVR, 1BOC). Among 
the seven trials which reported the proportion of African Americans and 
information on grade of fibrosis, two did not conduct subgroup analyses 
accordingly. Of the trials reporting prior viral load (8) and cirrhosis (5), only three 
and two trials presented related subgroup analyses, respectively. Severity of 
important safety endpoints such as rash and anemia was not defined in four of 
the studies (50%), mainly telaprevir trials, and neutropenia was not defined in 
almost two-thirds (5/8). CONCLUSIONS: From an already small pool of studies to 
begin with, unavailability of data and lack of safety endpoint definitions are 
challenges that may reduce the feasibility and increase potential biases for 
conducting mixed treatment comparisons. Overcoming these identified 
challenges will improve understanding of the comparative efficacy and safety of 
HCV drugs, particularly in the at-risk population.  
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OBJECTIVES: This study aimed to assess the association of Crohn’s disease 
prevalence with demographic characteristics in the U.S. veteran population. 
METHODS: This study analyzed a patient sample from the Veterans Health 
Administration (VHA) Medical SAS datasets from October 1, 2005 to May 31, 2012. 
All patients diagnosed with Crohn’s disease during 2011 were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 555. Patients with medical benefits enrollment not covering 
2011 were excluded. Study patient demographic information was then captured 
and categorized into groups. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: For VHA patients diagnosed in 2011 with 
Crohn’s disease (N=41,418), prevalence varied by race as follows: Non-Hispanic 
White (0.23%), Non-Hispanic Black (0.14%), Hispanic (0.09%) and other races 
(0.13%). When stratified by age, the highest prevalence was observed in the 
higher age groups: 55-64 (0.21%), 35-54 (0.20%), and 65+ (0.17%). Based on the 
examination of Crohn’s disease prevalence in different states, the disease was 
found to be most likely diagnosed in Maine (0.35%), Vermont (0.29%), Connecticut 
(0.28%) and New Hampshire (0.24%). On the contrary, Puerto Rico (0.07%), 
Washington D.C. (0.07%) and Hawaii (0.06%) showed the lowest prevalence. 
However, the difference was never greater than 0.3%. CONCLUSIONS: The 
uneven distribution of Crohn’s disease among U.S. states suggests a geographic 
variation in risk areas that may be useful for future targeted intervention 
strategies. Further research may be necessary for middle-aged and elderly 
patient groups to prevent this disease.  
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OBJECTIVES: To estimate pharmacy and overall budgetary impact of introducing 
linaclotide to a hypothetical one-million-member managed care plan. 
METHODS: A decision-tree model (one-year time horizon) was constructed to 
estimate the budgetary impact of linaclotide. Model inputs include plan 
population, treatment costs, estimated current and future monthly prescription 
utilization, response rates, and potential medical cost offsets. Model outputs are 
per-member per-month (PMPM) pharmacy and medical costs. Treatment options 
include linaclotide, lubiprostone, and other prescription therapies. The 
proportion of patients who respond to linaclotide are assumed to incur lower 
health care costs due to less health care utilization. Treatment costs are based 
on published prices (polyethylene glycol, the most common prescription therapy 
is used as a surrogate for other generically-available prescription therapies). 
Daily net treatment costs (payer perspective) are $5.50, $6.37, and $0.29 for 
linaclotide, lubiprostone, and polyethylene glycol, respectively. Current 
prescription utilization (14% lubiprostone, 86% other therapies) and potential 
annual per-patient medical cost offsets (IBS-C: $1781, CC: $2002) are derived from 
retrospective database analyses; future prescription utilization (8% linaclotide, 
10% lubiprostone, 82% other) is assumed. Linaclotide response rates (IBS-C: 
33.6%, CC: 18.6%) are from primary endpoints of Phase III clinical trials. 
Budgetary impact is calculated as the cost difference between current and future 
scenarios. One-way sensitivity analyses were performed. RESULTS: Introducing 
linaclotide to a managed care formulary is estimated to increase the pharmacy 
budget by $0.007 PMPM; when potential medical cost offsets are included, the 
resulting overall budgetary impact is estimated to be $0.003 PMPM. In sensitivity 
analyses, number of linaclotide patients, IBS-C cost offsets, and conversion from 
other therapies to linaclotide had the greatest influence on budgetary impact; 
however, results did not vary substantially from base-case. CONCLUSIONS: 
Linaclotide is expected to result in a slight increase in pharmacy budgets which 
may be partially offset by medical cost savings.  
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OBJECTIVES: Hepatitis C virus (HCV) infection is a chronic disease affecting the 
liver that may lead to cirrhosis and result in costly outcomes including ascites, 
variceal bleeds, encephalopathy, hepatocellular carcinoma (HCC), and liver 
transplant. The purpose of this study is to evaluate the overall cost burden of 
genotype 1 chronic HCV patients treated with current triple therapy regimens 
(protease inhibitor/peginterferon alfa/ribavirin) or future quadruple therapy 
regimens (polymerase or NS5A inhibitor/protease inhibitor/peginterferon 
alfa/ribavirin), and the incremental cost burden of patients identified as having 
chronic HCV by new screening guidelines. METHODS: A 50-year Markov cohort 
model was developed to compare current and future HCV treatment regimens. 
Patients who achieved sustained virologic response (SVR) were considered 
responders and were assigned a decreased level of progression to HCC, liver 
transplant, and liver-related mortality. Cost inputs, including pharmacy and 
medical costs associated with progressive HCV-related liver disease, were 
derived from published sources and Redbook. Treatment effectiveness, 
adherence rates, and transition probabilities for responders and non-responders 
were derived from published sources. SVR for quadruple therapy was derived 
from interim phase II trial results. Cost and outcomes were discounted at 3% and 
tested with a one-way sensitivity analysis. RESULTS: The discounted cost to 
treat a patient with triple therapy is US$150,790, including pharmacy costs and 
hepatic sequelae. Assuming treatment at time of drug approval, the 
corresponding discounted cost for quadruple therapy is projected at US$205,045 
per patient. Based on proposed screening guidelines, approximately 150,000 
additional chronic HCV patients will be both diagnosed and treated. The 
incremental discounted cost of treating these additional patients with quadruple 
therapy is projected to be $28.5 billion and is due in part to increased patient 
lifespan. CONCLUSIONS: New screening guidelines and therapeutic advances are 
projected to improve patient utilization of more effective treatments and result 
in an increased level of health care spending.  
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